Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...
Shanghai Healthcare Capital
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...